Skip to content

Comparison of the Effect of Inhaled Spray of Symbicort with Zenhale.

Comparison of the Effect of Inhaled Spray of Symbicort and Zenhale in Assessing Patients in Stage 3 and 4 with Asthma.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150107020592N17
Enrollment
150
Registered
2018-02-27
Start date
2017-08-23
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Asthma are in stage of 3 and 4.. Asthma

Interventions

Intervention 1: Intervention group: 75 patients were in the group receiving budesonide / Formetrol. Intervention 2: Intervention group: 75 patients were in the group receiving Mometazone / Formetrola

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients Over 12 years old Asthma diagnosed using spirometry with and without salbutamol Patients should be placed in stages 3 and 4 in terms of severity of the disease.

Exclusion criteria

Exclusion criteria: Cardiovascular patients Asthma attack has led to hospitalization in the last six months BMI above 35 Chronic illnesses, such as occupational diseases Chronic obstructive pulmonary disease Interstitial lung disease Nasal polyps and sinusitis Esophageal reflux Heart failure Oral candidiasis Desphony Pregnancy smokers People with specific food allergies

Design outcomes

Primary

MeasureTime frame
Use of salbutamol. Timepoint: Less than twice a week / more than twice a week. Method of measurement: questionnaire.

Secondary

MeasureTime frame
Forced Expiratory Volume in One Second (FEV1). Timepoint: Pre and post intervention. Method of measurement: Spirometry.;Duration of hospitalization. Timepoint: After intervention. Method of measurement: questionnaire.;Number of night paroxysmal in a month. Timepoint: After intervention. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohamadreza Hashemian

The Edjucational , Research and Treatment center

iran.criticalcare@yahoo.com+98 21 2111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026